Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial

CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET inhibitor. More than one-third of patients reported a reduction in dyspnea during study participation and nearly half reported a reduction in pain by the first-follow up assessment.PMID:34523767 | DOI:10.1002/onco.13976
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research